Short-Term Debt to Equity Ratio: Scilex Holding Company (SCLX)
Cash flows for Scilex Holding Company (SCLX) remain resilient due to the sale of pain management treatments. The business operates within its own product cycle, insulated from global market volatility, which gives the asset defensive qualities. The model generates revenue based on drug efficacy, aiming to expand insurance coverage and create safe opioid alternatives. The price history of the shares with the 0.00 metric is shown in the chart below.
Analytical breakdowns and data insights for company scilexholding.com (SCLX)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
- company profitability and valuation multiples indicators:
Fundamental company analysis:Scilex Holding Co.
The long-term sustainability of Scilex Holding Company (SCLX) is determined by its ability to service current liabilities without compromising assets. This indicator measures the share of short-term loans within the capital structure, identifying refinancing risks during periods of volatility. By analyzing the trend of loans with maturities up to one year relative to equity, an investor assesses the balance between financial leverage and security. Stable cash flow from the sale of non-opioid patches allows Scilex Holding Company (SCLX) to effectively control this metric.
Main competitors
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|Short-Term Debt to Equity Catalyst Pharmaceuticals|denalitherapeutics.com (DNLI) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital HRMY|Short-Term Debt to Equity Ratio Biohaven Ltd BHVN|Short-Term Debt to Capital AMLX (Amylyx)|Short-Term Debt to Capital Coefficient Trevi Corp (TRVI)|PRAX - Short-Term Debt to Equity|AVXL: Short-Term Debt to Equity|CBLL: Short-Term Debt to Capital|Current Liabilities to Capital Prothena Biosciences (PRTA)|Short-Term Debt to Equity Ratio ALEC|Short-Term Debt to Capital Ratio ANNX (Annexon Biosciences Inc.)|Short-Term Debt to Equity Ratio OMER (Omeros Corporation)|NGNE (neurogene.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ACIU (AC Immune SA)|Ratio of Short-Term Indebtedness to Capital VYGR|NMRA - Short-Term Debt to Equity|Current Liabilities to Capital Tevogen Bio Inc.|alphacognition.com (ACOG) - Short-Term Debt to Equity|CGTX (cogrx.com) - Short-Term Debt to Equity|IKT (Inhibikase Therapeutics, Inc.) - Short-Term Debt to Capital|Short-Term Debt to Capital Ratio SAVA (Cassava Sciences Inc)|Short-Term Debt to Capital ASRT|Short-Term Debt to Capital Coefficient coyatherapeutics.com|Short-Term Debt to Equity Vistagen VTGN|OVID: Short-Term Debt to Capital Ratio|Acumen Pharmaceuticals, Inc. - Short-Term Debt to Capital|Short-Term Indebtedness to Equity CervoMed, Inc. (CRVO)|ATHE (alteritytherapeutics.com) - Short-Term Debt to Equity Ratio|Clene - Ratio of Short-Term Indebtedness to Capital|PEPG (PepGen Inc) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio jupiterneurosciences.com (JUNS)|Short-Term Debt to Equity Relmada Therapeutics, Inc. (RLMD)|ANVS - Current Liabilities to Capital|Short-Term Debt to Equity Grace Therapeutics GRCE|AIFF - Short-Term Debt to Equity Ratio|KLTO - Short-Term Debt to Equity|Current Liabilities to Equity NRSN|RVPH: Short-Term Debt to Capital|MetaVia (MTVA) - Short-Term Debt to Capital|Short-Term Debt to Equity NeurAxis, Inc|Short-Term Debt to Capital Ratio HSDT (Helius Medical Technologies Inc.)|Short-Term Debt to Equity Ratio PASG (Passage Bio, Inc.)|NEUP - Current Liabilities to Capital|Short-Term Debt to Equity Minerva Neurosciences, Inc. NERV|Short-Term Debt to Capital Coefficient Athira Pharma Inc (ATHA)|Addex Therapeutics, Ltd. - Short-Term Debt to Capital|Alzamend Neuro, Inc. (ALZN) - Short-Term Debt to Equity Ratio|cyclerion.com (CYCN) - Short-Term Debt to Equity|PTIX (Protagenic Therapeutics, Inc.) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio KTTA|Short-Term Debt to Capital Ratio CRGT (Cortigent Medical)|Short-Term Debt to Equity Avenue Therapeutics, Inc (ATXI)|BrainStorm Cell Therapeutics Inc. - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital CARA (Cara Therapeutics, Inc.)|chromocell.com (CHRO) - Current Liabilities to Capital|ELYM: Short-Term Debt to Equity Ratio|ITCI - Short-Term Debt to Capital|Longboard Pharma (LBPH) - Short-Term Debt to Equity|Marinus Pharma - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity NKGen Biotech, Inc.|Current Liabilities to Capital neurobopharma.com NRBO|Short-Term Debt to Equity Sage Therapeutics (SAGE)|Short-Term Debt to Capital Coefficient Synaptogenix Inc.|Short-Term Debt to Capital TRVN (Trevena, Inc)|VIGL - Short-Term Debt to Equity Ratio|Anew Medical, Inc. - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient cerevel.com CERE